2026 Q2 -tulosraportti
Vain PDF
5 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 334 | - | - | ||
| 360 | - | - | ||
| 992 | - | - | ||
| 84 | - | - | ||
| 1 063 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuBut will it continue to bleed until new collaboration agreements or the results from their phase 1 studies come? It's quite a big drop it has made from the top, but the shorters have been right and now they are almost out 0.22 % and it's still falling, one must not hope that the shorters come back,
Something needs to happen regarding the capital. Not many have made proper calculations - they think everything will be fixed with a couple of upfront from existing partnerships - but that's not enough. I haven't fully checked that they are now pausing one and only continuing with 2 initially - that is clearly positive. But for everyone who bothered to spend a little time on it, it was quite obvious that they would have to go through a capital increase no later than the end of 2027 if they wanted to start 2 up ult 2026 and 1 up in start 2027 - so it's really sensible (and for me not unexpected) that they are pausing one until they possibly have made another agreement from their library. Some of the "triggers" that are in place must be activated before it moves on from here. - initiation/progress of the partner programs (both the progress and miletstones is positive - a clarification of Tesonfensine in Mexico (it's almost at the point where even a rejection can be positive due to clarification - now we don't have to think about it anymore) - something they can push the possible capital need further into 2028-2029. As I have said many times by now, my stance remains 12-15 - and my guess is that it is the capital issue that has pushed it further here. I am relatively calm with my GAK at 13,94 - bought from March onwards, when it returned to more reasonable/realistic levels.- ·28.8.Today is a good sign that it's no longer the speculators and retail investors who control the price. It looks like it's finally the professional market and not small investors in Discord or Facebook groups who control the price. Unambiguously positive - without changing the fair value of 12-15 - that they are pausing one of the programs. This reduces the risk of the share issuance I previously stated as necessary in 2027. Nice to see the price didn't drop on the decision to pause one of the internal projects. I do hope that someone goes crazy for a potential agreement on a new project and the first milestones - I would like to sell some at price 20 - I have (again) bought a bit too many in this preclinical high-risk company 😀. Should it reach 25-30 during 2027, everything will go again with a nice profit - can always buy again at 20 afterwards
- ·26.8.Some must surely expect that bad news will come tomorrow on earnings day with the decline it has had recently, we thought we had reached the bottom but it doesn't look like it, we must wait until tomorrow and see what happens, but I don't like that there are so many on the seller side and few on the buyer side and that it is only shorted by 0,22 %
Biohaven agreement kv7 against focal epilepsy 400 million dollars upfront phase2/3. Saniona is mentioned. 
·21.8.Selling this shit soon 
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
5 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuBut will it continue to bleed until new collaboration agreements or the results from their phase 1 studies come? It's quite a big drop it has made from the top, but the shorters have been right and now they are almost out 0.22 % and it's still falling, one must not hope that the shorters come back,Something needs to happen regarding the capital. Not many have made proper calculations - they think everything will be fixed with a couple of upfront from existing partnerships - but that's not enough. I haven't fully checked that they are now pausing one and only continuing with 2 initially - that is clearly positive. But for everyone who bothered to spend a little time on it, it was quite obvious that they would have to go through a capital increase no later than the end of 2027 if they wanted to start 2 up ult 2026 and 1 up in start 2027 - so it's really sensible (and for me not unexpected) that they are pausing one until they possibly have made another agreement from their library. Some of the "triggers" that are in place must be activated before it moves on from here. - initiation/progress of the partner programs (both the progress and miletstones is positive - a clarification of Tesonfensine in Mexico (it's almost at the point where even a rejection can be positive due to clarification - now we don't have to think about it anymore) - something they can push the possible capital need further into 2028-2029. As I have said many times by now, my stance remains 12-15 - and my guess is that it is the capital issue that has pushed it further here. I am relatively calm with my GAK at 13,94 - bought from March onwards, when it returned to more reasonable/realistic levels.
- ·28.8.Today is a good sign that it's no longer the speculators and retail investors who control the price. It looks like it's finally the professional market and not small investors in Discord or Facebook groups who control the price. Unambiguously positive - without changing the fair value of 12-15 - that they are pausing one of the programs. This reduces the risk of the share issuance I previously stated as necessary in 2027. Nice to see the price didn't drop on the decision to pause one of the internal projects. I do hope that someone goes crazy for a potential agreement on a new project and the first milestones - I would like to sell some at price 20 - I have (again) bought a bit too many in this preclinical high-risk company 😀. Should it reach 25-30 during 2027, everything will go again with a nice profit - can always buy again at 20 afterwards
- ·26.8.Some must surely expect that bad news will come tomorrow on earnings day with the decline it has had recently, we thought we had reached the bottom but it doesn't look like it, we must wait until tomorrow and see what happens, but I don't like that there are so many on the seller side and few on the buyer side and that it is only shorted by 0,22 %Biohaven agreement kv7 against focal epilepsy 400 million dollars upfront phase2/3. Saniona is mentioned.
- ·21.8.Selling this shit soon
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 334 | - | - | ||
| 360 | - | - | ||
| 992 | - | - | ||
| 84 | - | - | ||
| 1 063 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |
2026 Q2 -tulosraportti
Vain PDF
5 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 27.8. | ||
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuBut will it continue to bleed until new collaboration agreements or the results from their phase 1 studies come? It's quite a big drop it has made from the top, but the shorters have been right and now they are almost out 0.22 % and it's still falling, one must not hope that the shorters come back,Something needs to happen regarding the capital. Not many have made proper calculations - they think everything will be fixed with a couple of upfront from existing partnerships - but that's not enough. I haven't fully checked that they are now pausing one and only continuing with 2 initially - that is clearly positive. But for everyone who bothered to spend a little time on it, it was quite obvious that they would have to go through a capital increase no later than the end of 2027 if they wanted to start 2 up ult 2026 and 1 up in start 2027 - so it's really sensible (and for me not unexpected) that they are pausing one until they possibly have made another agreement from their library. Some of the "triggers" that are in place must be activated before it moves on from here. - initiation/progress of the partner programs (both the progress and miletstones is positive - a clarification of Tesonfensine in Mexico (it's almost at the point where even a rejection can be positive due to clarification - now we don't have to think about it anymore) - something they can push the possible capital need further into 2028-2029. As I have said many times by now, my stance remains 12-15 - and my guess is that it is the capital issue that has pushed it further here. I am relatively calm with my GAK at 13,94 - bought from March onwards, when it returned to more reasonable/realistic levels.
- ·28.8.Today is a good sign that it's no longer the speculators and retail investors who control the price. It looks like it's finally the professional market and not small investors in Discord or Facebook groups who control the price. Unambiguously positive - without changing the fair value of 12-15 - that they are pausing one of the programs. This reduces the risk of the share issuance I previously stated as necessary in 2027. Nice to see the price didn't drop on the decision to pause one of the internal projects. I do hope that someone goes crazy for a potential agreement on a new project and the first milestones - I would like to sell some at price 20 - I have (again) bought a bit too many in this preclinical high-risk company 😀. Should it reach 25-30 during 2027, everything will go again with a nice profit - can always buy again at 20 afterwards
- ·26.8.Some must surely expect that bad news will come tomorrow on earnings day with the decline it has had recently, we thought we had reached the bottom but it doesn't look like it, we must wait until tomorrow and see what happens, but I don't like that there are so many on the seller side and few on the buyer side and that it is only shorted by 0,22 %Biohaven agreement kv7 against focal epilepsy 400 million dollars upfront phase2/3. Saniona is mentioned.
- ·21.8.Selling this shit soon
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 334 | - | - | ||
| 360 | - | - | ||
| 992 | - | - | ||
| 84 | - | - | ||
| 1 063 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
No funds report this stock among their ten largest holdings.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 381 028 | 381 028 | 0 | 0 |